JPMorgan analyst Eric Joseph raised the firm’s price target on Vir Biotechnology (VIR) to $14 from $10 and keeps a Neutral rating on the shares. The firm believes initial clinical data for Vir’s in-sourced masked T-cell engager candidates support promising and potentially competitive activity profiles in key solid tumor subsets, that altogether affirm the platform as a strategically solid acquisition from Sanofi (SNY). Given the assets are still in the early phase of development via dose escalation, the firm believes it will take both a clearer sense of additional cohorts cleared for safety and numbers of evaluable subjects into the next readout for shares to sustain upside momentum.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VIR:
- Exxon and Shell cautious on Q4, Flutter cuts guidance: Morning Buzz
- Vir Biotechnology Reports Promising Trial Results for Cancer Therapies
- Vir Biotechnology presents safety, efficacy data in VIR-5818 and VIR-5500 trials
- Vir Biotechnology price target lowered to $14 from $15 at BofA
- FDA revokes EUAs for some antibody treatments for COVID-19
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
